News

Panel supports lower doses of novel insomnia drug

Publish date: May 23, 2013

 

FROM AN FDA ADVISORY PANEL MEETING

Panelists have been cleared of potential conflicts of interest related to the topic of the meeting. Occasionally, a panelist may be given a waiver, but not at this meeting.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

FDA Reviewing Possible Heart Failure Risk with Pramipexole
MDedge Internal Medicine
Zolpidem Linked to Higher Inpatient Fall Rates
MDedge Internal Medicine
Acetazolamide and CPAP combined improve OSA at high altitude
MDedge Internal Medicine
FDA requires lower recommended doses for certain sleep drugs
MDedge Internal Medicine
Renal denervation improves glucose metabolism, sleep apnea
MDedge Internal Medicine
CPAP vs. appliances for sleep apnea
MDedge Internal Medicine
For hypertension, pair CPAP with weight loss
MDedge Internal Medicine
REM sleep problems predict Parkinson's, Lewy body dementia
MDedge Internal Medicine
Older patients report frequent insomnia, sleep treatment use
MDedge Internal Medicine
Preclinical brain amyloid deposition linked to poor sleep
MDedge Internal Medicine